Subscribe To
Syfovre® (pegcetacoplan injection) continued to demonstrate increasing treatment effects over 3 years in patients with geographic atrophy (ga)
SYFOVRE reduced nonsubfoveal GA lesion growth by over 40% (monthly) in Year 3 compared to projected sham in the GALE extension study Well-demonstrated...
November 4, 2023, 5:37 pm
Seeking high dividends? 3 fairly valued/undervalued high dividend yield stocks for your portfolio
High dividend yield companies are valuable assets for your portfolio, since they are a great way to generate added income, which you can reinvest or u...
November 4, 2023, 3:00 pm
Candel therapeutics presents preclinical data from its enlighten™ discovery platform at sitc
The first experimental agent from the enLIGHTEN™ Discovery Platform is Alpha-201-macro1, an investigational viral immunotherapy designed to activate...
November 4, 2023, 12:00 pm
Kddi corporation (kddiy) q2 2024 earnings call transcript
KDDI Corporation (OTCPK:KDDIY) Q2 2024 Results Conference Call November 2, 2023 2:30 AM ET Company Participants Makoto Takahashi - President, Represen...
November 4, 2023, 11:48 am
Morgan stanley: grab a 6.5% dividend yield from preferred shares
Morgan Stanley's Q3 financial results showed a decrease in wealth management revenue but higher margins. The bank only needed 6% of its net income to ...
November 4, 2023, 11:40 am
Allient inc. (alnt) q3 2023 earnings call transcript
Allient Inc. (NASDAQ:ALNT ) Q3 2023 Earnings Conference Call November 2, 2023 10:00 AM ET Company Participants Craig Mychajluk - Investor Relations Ri...
November 4, 2023, 11:37 am
Nie: discounted but not a bargain
The Virtus Equity & Convertible Income Fund is benefiting from its heavy exposure to mega-cap tech stocks, leading to a solid performance in 2023. The...
November 4, 2023, 9:45 am
Hugo boss ag (bossy) q3 2023 earnings call transcript
HUGO BOSS AG (OTCPK:BOSSY) Q3 2023 Earnings Conference Call November 2, 2023 6:00 AM ET Company Participants Yves Müller - CFO & COO Christian Stohr ...
November 4, 2023, 8:52 am
Endesa, s.a. (elezf) q3 2023 earnings call transcript
Endesa, S.A. (OTCPK:ELEZF) Q3 2023 Earnings Conference Call October 31, 2023 5:00 AM ET Company Participants Mar Martinez - Investor Relations Jose Bo...
November 4, 2023, 7:33 am
Japan tobacco inc. (japaf) q3 2023 earnings call transcript
Japan Tobacco Inc. (OTCPK:JAPAF) Q3 2023 Earnings Conference Call October 31, 2023 4:00 AM ET Company Participants Hiromasa Furukawa - CFO Conference ...
November 4, 2023, 6:59 am
Buy hershey amid financial and technical strength
The Hershey Company reported strong Q3 2023 financial results, with a substantial increase in net sales driven by organic sales growth and strategic p...
November 4, 2023, 6:23 am
Otlk investor alert: robbins geller rudman & dowd llp announces that outlook therapeutics, inc. investors with substantial losses have opportunity to lead the outlook therapeutics class action lawsuit
SAN DIEGO, Nov. 03, 2023 (GLOBE NEWSWIRE) — Robbins Geller Rudman & Dowd LLP announces that the Outlook Therapeutics class action lawsuit seeks to r...
November 4, 2023, 12:13 am
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...
November 3, 2023, 11:30 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...
November 3, 2023, 11:30 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...
November 3, 2023, 11:30 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...
November 3, 2023, 11:30 pm
Lgi homes, inc. reports october 2023 home closings
THE WOODLANDS, Texas, Nov. 03, 2023 (GLOBE NEWSWIRE) — LGI Homes, Inc. (NASDAQ: LGIH) today announced it closed 560 homes in October 2023, up from 5...
November 3, 2023, 9:05 pm
Elicio therapeutics presents updated preliminary immunogenicity data from the ongoing phase 1 study of eli-002 and new preclinical data on eli-007 and eli-008 at the society for immunotherapy of cance
In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an investigational therapeutic cancer vac...
November 3, 2023, 8:30 pm
Elicio therapeutics presents updated preliminary immunogenicity data from the ongoing phase 1 study of eli-002 and new preclinical data on eli-007 and eli-008 at the society for immunotherapy of cance
In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an investigational therapeutic cancer vac...
November 3, 2023, 8:30 pm
Sensei biotherapeutics reports favorable clinical data for sns-101 at 2023 sitc annual meeting
– Clinical dose escalation data for SNS-101 monotherapy show well tolerated safety profile, potentially best-in-class pharmacokinetics, and encourag...
November 3, 2023, 8:05 pm